NUPR1 a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

ABSTRACT: Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits is modest, also because its mechanism of action remains elusive, therefore, a better understanding of its molecular action and molecular targets are needed. On the basis of our previous studies, here, we investigated the role of the nuclear protein 1 (NUPR1) in HCC and its role in the context of sorafenib treatment. NUPR1 is a stress-inducible protein over-expressed in different malignancies, however, its role in HCC is not yet fully understood. We found that NUPR1, is over-expressed in 53% of primary human HCC samples. Knockdown of NUPR1 significantly increased cell sensitivity to sorafenib and inhibits cell growth, migration and invasion

ORGANISM(S): Homo sapiens

SUBMITTER: Dimcho Bachvarov 

PROVIDER: E-GEOD-73521 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress